Portal’s Houston portfolio company CrossBridge Bio acquired by Eli Lilly!

Portal’s Houston-based portfolio company focused on ADCs, CrossBridge Bio, was acquired by Eli Lilly in a deal worth up to $300 million! Congratulations to the CrossBridge Bio team!